Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

INCA035784

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloproliferative NeoplasmsRecruiting

Myeloproliferative NeoplasmsPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Myeloproliferative Neoplasms

NCT07008118

Clinical

Trials by Indication[1]

Myeloproliferative Neoplasms1 trial

A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms

Recruiting· Incyte logo

Incyte·Phase 1·NCT07008118·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INCA035784. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCA035784 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCA035784. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Incyte

Related News